CMHC to provide ‘exciting’ updates spanning cardio-kidney-metabolic sector
Click Here to Manage Email Alerts
Key takeaways:
- The Cardiometabolic Health Congress takes place Oct. 17-19 in Boston.
- The meeting will feature four main sessions with presentations that span the field of cardio-kidney-metabolic care and more.
The 19th annual Cardiometabolic Health Congress will be held at the Boston Park Plaza and will feature the latest science in the areas of cardio-renal, obesity, diabetes and dyslipidemia, atherosclerosis, thrombosis and more.
Healio spoke with Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of cardiovascular research, professor of medicine at Baylor College of Medicine and co-chair of the Cardiometabolic Health Congress (CMHC), about what attendees can look forward to at this year’s meeting.
“It's a wonderful, smaller meeting, and a chance to meet with all the faculty, have case discussions, and it really covers some rapidly moving areas related to cardiometabolic health,” Ballantyne told Healio.
The congress kicks off with an FDA update, a rundown of key late-breaking clinical trials and a keynote address by Peter Libby, MD, titled “Prevention and Treatment of Atherosclerosis.”
“One of the things I love is the initial session on FDA updates and late-breaking trials, because it takes you quickly through all the big things that happened in the last year in the areas of thrombosis with Deepak L. Bhatt, MD, MPH, obesity with Robert H. Eckel, MD, hypertension with Keith C. Ferdinand, MD, and kidney disease with Anne L. Peters, MD; I go through lipids,” Ballantyne told Healio. “We have a fantastic keynote speaker, Peter Libby, MD, who is going to give us an update on prevention and treatment of atherosclerosis.”
On Thursday, session I will focus on the latest updates in the field of cardio-renal care.
“There has been a tremendous amount of progress in this area in terms of ... therapies to slow the progression of chronic kidney disease. It has been very dynamic what's happening [in cardio-renal care],” he said. “There's also a tribute to George L. Bakris, MD. George was one of the leaders [in this area], a nephrologist and hypertension expert who pushed this field forward. If you think about the kidney-metabolic axis, George led the way.”
On Friday, the day begins with session II, with a focus on obesity. Presentations will highlight behavioral interventions, ultraprocessed food addiction, obesity pharmacotherapy, sleep disorders and surgical approaches to obesity.
“This is probably the biggest, hottest area in medicine right now. If we look at where we were when we started doing this almost 20 years ago, the data that came out since the SELECT study — the first trial that showed that treating obesity significantly reduced CV events — we now have so much more in the pipeline,” Ballantyne said. “We have great information on the new drugs, but there's always a big focus on lifestyle too. We have a session on ultraprocessed food addiction signs and solutions and another on sleep disorders, which is a really important part of cardiometabolic health. And we will also have a presentation on surgical approaches to obesity. That's going to be a great day.”
Friday will also feature session III, covering the topic of diabetes. The session will spotlight precision medicine in diabetes, initiating and maintaining insulin therapy and two presentations on continuous glucose monitoring.
“Continuous glucose monitoring has expanded beyond diabetes to prediabetes, and it is now also helping people to improve their lifestyle. To me, that's really exciting,” Ballantyne said.
On Saturday, the meeting is scheduled to wrap up with session IV, featuring updates in dyslipidemia, atherosclerosis and thrombosis.
“There is a lot happening in terms of very severe triglycerides. We’ve got some new therapies to be able to treat people,” he said. “Another hot area is lipoprotein(a), which is not being measured much currently but it’s a very important genetic risk factor. Then we'll go over how we manage these patients with lipid disorders.”
Healio is an official media partner of CMHC. The Healio team will provide coverage from the meeting, including reports on the sessions above and more. Follow along at this link and on X (Twitter) at @CardiologyToday.
For more information:
The CMHC agenda and more information is available at https://www.cardiometabolichealth.org/19th-annual-cmhc/.
Collapse
Healio Interviews
Click Here to Manage Email Alerts